These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32477525)

  • 1. Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vitiligo, and plaque and inverse psoriasis.
    Tajalli M; Kabir S; Vance TM; Qureshi AA
    Clin Case Rep; 2020 May; 8(5):819-822. PubMed ID: 32477525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy.
    Perche P; Purvis C; Pichardo R
    J Drugs Dermatol; 2022 Dec; 21(12):1366-1368. PubMed ID: 36468955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of targeted narrowband UVB therapy: a retrospective cohort study.
    Esen Salman K; Kıvanç Altunay İ; Salman A
    Turk J Med Sci; 2019 Apr; 49(2):595-603. PubMed ID: 30997975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
    Di Lernia V; Bardazzi F
    Drug Des Devel Ther; 2016; 10():533-9. PubMed ID: 26889081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alexithymia in different dermatologic patients.
    Dehghani F; Dehghani F; Kafaie P; Taghizadeh MR
    Asian J Psychiatr; 2017 Feb; 25():42-45. PubMed ID: 28262172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib.
    Lin Q; Zhu J; Gao X
    Clin Cosmet Investig Dermatol; 2024; 17():707-711. PubMed ID: 38524393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study.
    Huang J; Qian P; Tang Y; Li J; Liu F; Shi W
    Acta Derm Venereol; 2023 Dec; 103():adv12425. PubMed ID: 38112208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
    Yu DA; Kim YE; Kwon O; Park H
    Indian J Dermatol Venereol Leprol; 2021; 87(5):621-627. PubMed ID: 34379968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silent celiac disease in dermatology.
    Real-Delor RE; Aldama-Negrete G; Aldama-Caballero A; Nunes-Tenace D; Aldama-Negrete F; Centurión-Medina I
    Rev Med Inst Mex Seguro Soc; 2020; 58(4):437-443. PubMed ID: 34543549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phototherapy in childhood.
    Ersoy-Evans S; Altaykan A; Sahin S; Kölemen F
    Pediatr Dermatol; 2008; 25(6):599-605. PubMed ID: 19067863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib in paediatric dermatoses: a narrative review.
    Agarwal I; Panda M; Das A
    Clin Exp Dermatol; 2022 Jul; 47(7):1256-1264. PubMed ID: 35279865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between skin diseases and quality of life: a comparison of psoriasis, vitiligo, and alopecia areata.
    Ghajarzadeh M; Ghiasi M; Kheirkhah S
    Acta Med Iran; 2012; 50(7):511-5. PubMed ID: 22930385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study: Classification: Epidemiology.
    Schneeweiss MC; Kirchgesner J; Wyss R; Jin Y; York C; Merola JF; Mostaghimi A; Silverberg JI; Schneeweiss S; Glynn RJ
    Br J Dermatol; 2022 Nov; 187(5):692-703. PubMed ID: 35718888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phototherapy in pediatric patients: choosing the appropriate treatment option.
    Pugashetti R; Koo J
    Semin Cutan Med Surg; 2010 Jun; 29(2):115-20. PubMed ID: 20579600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Tofacitinib: Contemporary Appraisal of Its Role in Dermatology.
    Sonthalia S; Aggarwal P
    Indian Dermatol Online J; 2019; 10(5):503-518. PubMed ID: 31544068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding autoimmunity of vitiligo and alopecia areata.
    Rork JF; Rashighi M; Harris JE
    Curr Opin Pediatr; 2016 Aug; 28(4):463-9. PubMed ID: 27191524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK-inhibitors in dermatology: current evidence and future applications.
    Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
    J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between psoriasis and alopecia areata: A systematic review and meta-analysis.
    Jung JM; Yang HJ; Lee WJ; Won CH; Lee MW; Chang SE
    J Dermatol; 2022 Sep; 49(9):912-915. PubMed ID: 35510645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study.
    Huang J; Deng S; Li J; Tang Y; Liu F; Liu Y; Rao S; Shi W
    Acta Derm Venereol; 2023 Nov; 103():adv13475. PubMed ID: 37955531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.